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Abstract
Background: Information on prescribing quality is increasingly used by policy makers, insurance companies and 
health care providers. For reliable assessment of prescribing quality it is important to correctly identify the patients 
eligible for recommended treatment. Often either diagnostic codes or clinical measurements are used to identify such 
patients. We compared these two approaches regarding the outcome of the prescribing quality assessment and their 
ability to identify treated and undertreated patients.
Methods: The approaches were compared using electronic health records for 3214 diabetes patients from 70 general 
practitioners. We selected three existing prescribing quality indicators (PQI) assessing different aspects of treatment in 
patients with hypertension or who were overweight. We compared population level prescribing quality scores and 
proportions of identified patients using definitions of hypertension or being overweight based on diagnostic codes, 
clinical measurements or both.
Results: The prescribing quality score for prescribing any antihypertensive treatment was 93% (95% confidence 
interval 90-95%) using the diagnostic code-based approach, and 81% (78-83%) using the measurement-based 
approach. Patients receiving antihypertensive treatment had a better registration of their diagnosis compared to 
hypertensive patients in whom such treatment was not initiated. Scores on the other two PQI were similar for the 
different approaches, ranging from 64 to 66%. For all PQI, the clinical measurement -based approach identified higher 
proportions of both well treated and undertreated patients compared to the diagnostic code -based approach.
Conclusions: The use of clinical measurements is recommended when PQI are used to identify undertreated patients. 
Using diagnostic codes or clinical measurement values has little impact on the outcomes of proportion-based PQI 
when both numerator and denominator are equally affected. In situations when a diagnosis is better registered for 
treated than untreated patients, as we observed for hypertension, the diagnostic code-based approach results in 
overestimation of provided treatment.
Background
In the last decade, many prescribing quality indicators
(PQI) have been developed to measure whether the right
drugs are prescribed to the right patients [1]. They are
being used for quality improvement initiatives, and to
identify and reward providers who meet predefined stan-
dards of quality. For assessing prescribing quality, it is
important to correctly identify the target population, i.e.
patients with a specific condition who should receive a
specific treatment. The validity of such identification
depends not only on source of data but also on the type of
information used to define a condition [2].
It has been recognized that the data source used can
influence the outcome of the quality assessment. Admin-
istrative data, which are created mainly for billing pur-
poses, often do not provide sufficient detail for reliable
quality assessment [3-5]. Medical records provide a good
alternative since they contain more detailed information
although it can be difficult to extract all relevant informa-
tion from this data source [6]. Aside from the data source,
the operational definition of a condition may influence
the outcome of the quality assessment. To identify the
target population, i.e. patients in need of a specific treat-
ment, either diagnostic codes or clinical measurements
indicative of a disease or condition can be used. For
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example, to assess the quality of treatment in patients
with hypertension, one can calculate the percentage of
patients with the diagnosis of hypertension prescribed
the recommended treatment [7-10], or the percentage of
patients with elevated blood pressure levels being pre-
scribed the recommended treatment [11-14].
These different approaches to define the target popula-
tion give rise to several possible problems. Using infor-
mation from recorded diagnoses can introduce bias due
to incomplete registration when some patients with a
condition do not have a corresponding diagnostic code
registered in the data or due to incorrectly registered
diagnostic codes[15,16]. Missing eligible patients is espe-
cially problematic for internal quality assessment, when
health care providers use PQI as screening tools to iden-
tify patients who may benefit from the improved treat-
ment. Using clinical measurements, on the other hand,
may lead to missing patients with well-controlled disease
states. In both cases, incorrect estimates of prescribing
quality can occur when the accuracy of identification is
not equal for treated and untreated patients. If this bias
varies between providers, it can introduce misclassifica-
tion on provider level and mislead pay-for-performance
programs when better score on quality indicators is
linked to financial incentives.
Little is known about the impact of the chosen
approach to define the target population on the assess-
ment of prescribing quality. The objective of our study
was to compare the approach based on diagnostic codes
r e g i s t e r e d  i n  e l e c t r o n i c  h e a l t h  r e c o r d s  ( E H R )  t o  t h e
approach based on clinical measurements registered in
EHR addressing the following questions:
1. Does the chosen approach affect prescribing qual-
ity scores?
2. What is the ability of the two approaches to identify
well treated and undertreated patients?
For this study, existing PQI were selected focusing on
glucose lowering and antihypertensive treatment in
patients with type 2 diabetes mellitus. This is a field
where both internal and external quality assessment are
bec o mi ng priori ty  f or hea lt h ca r e  sys t e ms,  a nd know l-
edge about the impact of the chosen approach to define
the target population is important for accurate and mean-
ingful quality measurement.
Methods
Study setting and sample
In The Netherlands, patients are registered with a single
general practitioner (GP) who has a gatekeeper role in
coordinating their medical care. Almost all GPs used
e l ec t r o n i c  h e a l t h  r ec o r d s.  F o r  o u r  s t u d y ,  w e  u s ed  d a t a
from all T2DM patients registered with 70 GPs working
in 37 practices in the North of the Netherlands. These
GPs participate in the GIANTT project that collects rou-
t i n e l y  d o c u m e n t e d  d a t a ,  s u c h  a s  d e m o g r a p h i c s ,  p r e -
scribed medication, diagnoses and clinical
measurements, from the EHR of the patients. An
approval to use the data for this study was obtained from
the Steering Committee of the GIANTT project was
obtained on April 7, 2006.
Patients with T2DM were identified through screening
of the electronic medical records of the GPs using text
terms for diabetes (including diab*, dm, type 2, type II),
diagnostic codes for diabetes (ICPC-code T90.x) [17],
record flags for diabetes, and diabetes medication (ATC-
code A10) [18]. All identified patients were classified by a
research assistant and verified by their GP as having type
2 diabetes mellitus using the WHO classification of dia-
betes [19]. In general, T2DM patients visit their GP every
three months, and routine blood pressure measurements
are usually conducted during these visits.
Data collection
An automatic data extraction method was used which
was described previously, and is very sensitive (97-100%)
in detecting relevant clinical measurement information,
e.g. blood pressure and body mass index (BMI) values,
irrespective of registration method or information system
used by the GP [20]. The method relies on text recogni-
tion to ensure retrieval of information from 'free text' seg-
ments of the records in addition to data collection from
structured tables, comparable to a manual chart review.
Diagnoses are collected from the problem lists in the
EHR where the GPs document medical problems pertain-
ing to the patient using either the International Classifi-
cation for Primary Care (ICPC) [17] coding or text lines,
which were manually recoded into the corresponding
I C P C  c o d e s  b y  t w o  r e s e a r c h e r s  v e r i f i e d  b y  a n  e x p e r i -
enced GP. All participating GPs prescribed electronically,
which means that the dataset included full information
regarding prescribed medication.
Prescribing quality indicators (PQI)
We included PQI that have been developed for assessing
prescribing quality in T2DM patients. These PQI were
derived from evidence-based diabetes guidelines, and
previously tested in expert panels [9,10,21,22]. For this
study, we selected two PQI focusing on the treatment of
patients with hypertension and one PQI focusing on glu-
cose management in obese or overweight patients. Both
hypertension and overweight can be defined using diag-
nostic codes or clinical measurement values, and the
required information is commonly available in the EHR
(table 1). These three PQI represent different aspects of
prescribing in different subgroups of T2DM patients. For
the first indicator (PQI-1), the clinical measurement is
directly influenced by the recommended treatment which
may result in missing patients with a well-controlled dis-Martirosyan et al. BMC Health Services Research 2010, 10:137
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ease state when using clinical measurements. This is
partly the case for PQI-2, although the recommended β-
blocker may not be the main treatment prescribed for
lowering the blood pressure. For PQI-3, there is no direct
effect of the recommended treatment on the control of
the condition.
Data analysis
All the analyses were conducted using data from the
EHR. The PQI were calculated using prescribing infor-
mation from the second half of 2004. All preceding diag-
nosis information regarding hypertension (ICPC-codes
K85, K86 and K87) and overweight or obesity (ICPC-
codes T82 and T83) was used for the diagnostic code-
based approach. For the clinical measurement-based
approach, an average systolic blood pressure (SBP) of
≥140 mmHg during the first half of 2004 was used to
define hypertensive patients, and the most recent BMI
value in 2004 being ≥25 was used to define overweight
patients. We used an average SBP ≥140 mmHg as a cut off
value to identify patients with hypertension following the
recommendations for treatment of T2DM patients with
hypertension described in the Dutch Hypertension
Guidelines for General Practitioners [23].
To check whether the inclusion of patients with an
'average' of only one elevated SBP value in the study
period might be unjustified, we assessed how many of
such patients had no preceding or next SBP values ≥140
mm/Hg. This was the case for only 2% of the patients
with elevated average SBP levels in the first half of 2004.
To select T2DM patients with history of ischemic heart
disease or myocardial infarction (PQI-2) we have used
ICPC codes K74, K76, and K75. All analyses were con-
ducted using SPSS version 16.0 (SPSS, Inc., Chicago, Illi-
nois).
To answer our first question, we calculated the PQI
scores with 95% confidence intervals using only diagnos-
tic codes or only clinical measurement values. The unit of
analysis for calculation of the PQI scores was an individ-
ual patient, therefore the prescribing quality scores dis-
cussed in this paper are population level scores. We used
mixed model analysis to adjust the scores of PQI and
their 95% confidence intervals for correlation within GP
practices. For our second question, we calculated the
ability of each approach to identify 'well treated' patients
(patients receiving the treatment as recommended), and
'undertreated' patients (patients in need of treatment but
not receiving the recommended treatment). This was
expressed as the proportion of 'well treated' (respectively
'undertreated') patients identified with either approach
from the total number of 'well treated' (respectively
'undertreated') patients identified with the reference
method, where we combined diagnostic codes with clini-
cal measurement values (box1).
Finally, we repeated the analyses in a subset of patients
that had at least one registered blood pressure or BMI
Table 1: Definitions of the PQI according to the diagnostic code-based approach, the clinical measurement-based 
approach, and the reference method
Diagnostic code-based Clinical measurement-based Reference (hybrid) method
PQI-1 Denominator: T2DM patients with 
diagnostic codes for hypertension
Denominator: T2DM patients with 
SBP≥140 mmHg
Denominator: T2DM patients with 
diagnostic codes for of hypertension OR 
SBP≥140 mmHg
Numerator: Denominator AND 
prescription of any antihypertensive 
medication
Numerator: Denominator AND 
prescription of any antihypertensive 
medication
Numerator: Denominator AND 
prescription of any antihypertensive 
medication
PQI-2 Denominator: T2DM patients with 
diagnostic codes for hypertension 
and history of IHD or MI
Denominator: T2DM patients with 
SBP≥140 mmHg AND history of IHD 
or MI
Denominator: T2DM patients with 
diagnostic codes for hypertension OR 
SBP≥140 mmHg AND history of IHD or MI
Numerator: denominator AND 
prescription of beta blocker
Numerator: Denominator AND 
prescription of beta blocker
Numerator: Denominator AND 
prescription of beta blocker
PQI-3 Denominator: T2DM patients with 
diagnostic codes for overweight OR 
obesity
Denominator: T2DM patients with 
BMI ≥25
Denominator: T2DM patients with 
diagnostic codes for overweight OR 
obesity OR BMI≥25
Numerator: Denominator AND 
prescription of metformin
Numerator: denominator AND 
prescription of metformin
Numerator: denominator AND 
prescription of metformin
T2DM: Type 2 Diabetes Mellitus, IHD: Ischaemic Heart Disease, MI: myocardial infarction, SBP: Systolic Blood Pressure, BMI: Body Mass Index 
(weight in kilograms divided by height in meters-squared)Martirosyan et al. BMC Health Services Research 2010, 10:137
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value during the study period to assess the impact of
incomplete registration of clinical measurements on the
comparison of the two approaches.
Results
The dataset included 3214 T2DM primary care patients
with an average age of 67 years and diabetes duration of 6
years; 55% were women (Table 2). Of the patients, 32%
had a registered diagnosis of hypertension, and 7% had a
diagnosis of overweight. Blood pressure measurements
were available for 80% of the patients, and BMI measure-
ments for 66% of patients. Among patients with regis-
tered measurements, 55% had an average systolic blood
pressure ≥140 mmHg, and 55% had a BMI ≥25.
Concurrence between registration of diagnostic codes
and the corresponding clinical measurements was low.
Among patients with an elevated systolic blood pressure,
62% (1086) did not have a registered diagnostic code for
hypertension. In case of overweight, 92% (1624) of
patients with BMI ≥25 did not have a registration of a
corresponding diagnostic code (table 3).
Scores of PQI
The choice of approach affected the outcome of only
PQI-1 focusing in prescription of any antihypertensive
treatment. For this PQI the diagnostic code-based
approach resulted in 12% higher prescribing quality score
than measurement-based approach. For the remaining
two indicators, the prescribing scores observed with dif-
ferent approaches were nearly identical (table 4).
Ability of identifying well treated and undertreated 
patients
The use of either diagnostic codes or clinical measure-
ments to identify well treated or undertreated patients
resulted in absolute differences in proportions of identi-
fied patients ranging from 15% to 84% (table 5). In all
cases, the measurement-based approach identified more
well treated and undertreated patients than the diagnos-
tic code-based approach. For well treated patients, the
proportion identified raised from 54% (diagnostic code-
based) to 84% (measurement-based) for antihypertensive
treatment in general (PQI-1), from 63% to 79% for beta
blocker treatment after ischemic heart diseases (PQI-2),
and from 12% to 97% for metformin treatment in over-
weight patients (PQI-3). Similarly, the proportion of
undertreated patients identified increased from 21%
(diagnostic code-based) to 88% (measurement-based) for
PQI-1, from 60% to 75% for PQI-2, and from 11% to 95%
for PQI-3 when clinical measurements were used (table
5).
Using the diagnostic code-based approach, a clear dif-
ference was observed in its ability to identify well treated
versus undertreated patients for antihypertensive treat-
ment in general (PQI-1). This approach identified 54% of
the well treated but only 21% of the undertreated
patients, indicating that the registration of a hypertension
diagnosis in the EHR is more likely when drug treatment
is initiated than when drug treatment is not (yet) initi-
ated. Such bias was not observed for the other two PQI
(table 5).
Subset analysis
We repeated the analyses in subsets of patients that had
at least one recorded blood pressure measurement for
PQI-1 (1939 of the 2070 hypertensive patients) and PQI-2
(227 of the 251 hypertensive patients with IHD or MI),
and at least one BMI value for PQI-3 (1772 of the 1837
overweight patients). The PQI scores for the subset were
quite similar to scores observed for the whole study pop-
ulation. According to the reference method, the prescrib-
ing quality scores calculated for the subsets changed from
81% to 82% for PQI-1, from 63% to 64% for PQI-2, and
remained 65% for PQI-3. For the diagnostic code-based
approach, observed changes were 92% to 94% (PQI-1),
65% to 66% (PQI-2), 65% to 70% (PQI-3). As could be
expected, the proportion of identified well treated and
Table 2: Characteristics of the study population (N = 3214)
Characteristic Value
Age, mean in years (SD) 67.1 (12.6)
Women, n (%) 1767 (55.0)
Duration of diabetes, mean in years (SD) 6.0 (5.6)
Registered diagnosis of hypertension, n (%) 984 (31.0)
Registered diagnosis of overweight or 
obesity, n (%)
213 (6.6)
Registered diagnosis of IHD or MI, n (%) 367 (11)
Registered systolic blood pressure, n (%) 2566 (79.8)
Registered Body Mass Index, n (%) 2106 (65.5)
Systolic blood pressure ≥140 mmHg, n (%) 1749 (54.4)
Body Mass Index ≥25, n (%) 1767 (55.0)
IHD: Ischaemic heart disease
MI: Myocardial infarctionMartirosyan et al. BMC Health Services Research 2010, 10:137
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undertreated patients with the measurement-based
approach increased for this subset of patients, and
approached the reference method with proportions of
89%, 86%, 100% for well treated and 95%, 85%, 100% for
undertreated patients.
Discussion
Our study showed that prescribing quality scores do not
necessarily change when using different approaches to
define the number of patients eligible for treatment.
However, when diagnosis is registered better for treated
than for untreated patients, as was the case for hyperten-
sion, the diagnostic code-based approach resulted in
overestimating the prescribing quality (93 versus 81%). In
addition, it became clear that incomplete registration of
diagnostic codes is a big problem for conditions such as
hypertension and overweight, leading to the identifica-
tion of low proportions of patients in need of treatment
(11-60%) when using a diagnostic code-based approach.
In general, PQI are proportion-based measures which
can be quite robust to changes in the numerator, as any
change in the numerator causes changes in the denomi-
nator [24]. This was the case for the indicators focusing
on the prescription of beta blockers and of metformin in
Table 3: Eligibility agreement between registration of diagnoses and clinical measurements
Diagnosis Diagnosis Total
Yes No
SBP ≥140 663 1086 1749
SBP < 140 190 627 817
No SPB 131 517 648
Total 984 2230 3214
BMI ≥25 143 1624 1767
BMI < 25 5 334 339
No BMI 65 1043 1108
Total 213 3001 3214
SBP: Systolic Blood Pressure
BMI: Body Mass Index (weight in kilograms divided by height in meters-squared)
Table 4: Scores of prescribing quality indicators identified with different approaches
Prescribing quality indicators (PQI) Outcome of the PQI, %, (95% CI) numerator/
denominator
Diagnostic code-based Measurement-based
PQI-1 Prescription of any antihypertensive medication in hypertensive 
T2DM patients
93(90-95)
1412/1749
81 (78-83)
905/984
PQI-2 Prescription of beta blocker in hypertensive T2DM patients with a 
history of IHD or MI
65(57-72)
100/155
64 (56-72)
125/194
PQI-3 Prescription of metformin in overweight T2DM patients 65(59-72)
39/213
66(62-69)
1154/1767
T2DM: Type 2 Diabetes mellitus
IHD: Ischaemic Heart Disease
MI: Myocardial InfarctionMartirosyan et al. BMC Health Services Research 2010, 10:137
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specific patient groups (PQI-2 and PQI-3). However, for
the indicator focusing on the prescription of any antihy-
pertensive drug (PQI-1), the diagnostic code-based
approach resulted in a higher score on prescribing quality
compared to the clinical measurements-based and refer-
ence methods. The explanation of this finding is that the
registration of the diagnostic codes for hypertension is
more likely once antihypertensive treatment is pre-
scribed, as was illustrated by the low percentage of
untreated in comparison to treated hypertensive patients
identified with the diagnostic code-based approach. A
similar finding was observed in non-diabetic population,
where treated patients also had a better registration of the
diagnosis of hypertension [25].
In our study population, the clinical measurement-
based approach identified higher proportion of patients
who are in need of treatment compared to the diagnostic
code-based approach. This is due to the fact that many
patients with either high blood pressure or BMI levels did
not have a registration of the corresponding diagnostic
code in the EHR. Poor registration of conditions such as
hypertension and especially overweight in the EHR seems
to be a common problem [26-28]. It has therefore been
advocated to use clinical measurements to improve docu-
mentation of such conditions [29]. Improved registration
of diagnostic codes as a part of quality improvement pro-
grams may make diagnostic code-based PQI more reli-
able. It is important to realize, however, that the validity
o f  r e g i s t e r e d  d i a g n o s e s  i s  i n f l u e n c e d  b y  m a n y  f a c t o r s
including the purpose of registration, skills and knowl-
edge of the coder, insensitive coding schemes for register-
ing specific diseases, prioritizing the coding of some
conditions over others by physicians, and completeness
of a disease classification system [15,30].
Clinical measurement values appear to be a better
choice for prescribing quality assessment, especially for
internal quality assurance, when it is crucial to correctly
identify as many patients who could benefit from the
improved treatment. When the clinical measurement val-
ues are influenced by the recommended treatment, as is
Table 5: Identification of well treated and undertreated patients using the diagnostic code-based and clinical 
measurement-based approach
Well treated patients Undertreated patients
Type of approach proportion 
detected*, %
N Proportion 
detected**, %
NN  o f  e l i g i b l e  
patients per PQI
PQI-1 Prescription of any antihypertensive medication in hypertensive T2DM patients 2070
Reference method - 1687 - 383
Diagnostic code-based, hypertension 54 (905/1687) 905 21 (79/383) 79
Measurement-based, SBP ≥140 84 (1412/1687) 1412 88 (337/383) 337
PQI-2 Prescription of beta blocker in hypertensive T2DM patients with a history of IHD or MI 251
Reference method - 159 - 92
Diagnostic code-based, hypertension 63 (100/159) 100 60 (55/92) 55
Measurement-based, SBP ≥140 79 (125/159) 125 75 (69/92) 69
PQI-3 Prescription of metformin in overweight T2DM patients 1837
Reference - 1193 - 644
Diagnostic code-based, overweight or obesity 12 (139/1193) 139 11 (74/644) 74
Measurement-based, BMI ≥25 97 (1154/1193) 1154 95 (613/644) 613
T2DM: Type 2 Diabetes mellitus
SBP: Systolic Blood Pressure
BMI: Body Mass Index (weight in kilograms divided by height in meters-squared)
*Number of treated patients detected through the tested approach divided by the number of treated patients according to the reference 
method
**Number of untreated patients detected through the tested approach divided by the number of untreated patients according to the 
reference methodMartirosyan et al. BMC Health Services Research 2010, 10:137
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the case for PQI-1 and PQI-2, a clinical measurement-
based approach for assessing the treatment may result in
missing patients with well-controlled disease states. This
is particularly a problem when patient eligibility and pre-
scribed treatment are assessed cross-sectionally [14].
When prescribing is assessed in a sequential way (i.e.
after the observed clinical measurement), as was done in
our study, missing well-controlled patients appeared not
to affect the quality scores. In situations where there are
already much higher percentages of well-controlled
patients, however, a measurement-based approach can
result in lower prescribing quality scores in comparison
to a diagnostic code-based approach.
In our study we used cut off levels of SBP ≥140 mmHg
t o  i d e n t i f y  p a t i e n t s  w i t h  h y p e r t e n s i o n  a s  a d v i s e d  b y
Dutch hypertension guidelines. However, World Health
Organization (WHO) and International Society of
Hypertension (ISH) advised to use lower cut off levels of
SBP to diagnose hypertension in T2DM patients [31]. Use
of lower values of SBP to identify hypertensive patients
may result in larger differences between the PQI scores
when the different approaches are used.
We used a sensitive method for data abstraction from
medical records. Registration of diagnostic codes was
complemented by recoding diagnoses from text lines.
Our reference method was based on a combination of
available information about diagnosis and measurements
documented in the EHR. Although EHR are often consid-
ered the gold standard for quality measurement, inade-
quate registration of both diagnoses and clinical
measurements affects this reference method. Our subset
analysis, however, showed that the prescribing quality
s c o r e s  w e r e  n o t  a f f e c t e d  b y  i n c o m p l e t e  r e g i s t r a t i o n  o f
clinical measurements. The PQI scores and proportions
of identified patients may not be generalizable to other
databases with different registration rates of clinical mea-
surements or diagnostic codes but the identified prob-
lems are likely to occur in other settings. The registration
rates in our dataset were similar to those described in
other studies conducted in different parts of the world
using EHR of both diabetic and general primary care
population [25,32,33].
Finally, it has to be kept in mind that if these PQI are
used for comparison of individual GPs, the number of eli-
gible patients per PQI per GP may not be sufficient for
reliable benchmarking. To address the problem of a small
sample size per PQI, one could choose from several exist-
ing methods including pooling data from several health
care providers or time periods or excluding indicators or
health care providers with small patient numbers [21].
Although in our study setting the ICPC codes were
used, we expect that the results of our study are also rele-
vant for health care systems using the International Clas-
sification of Diseases (ICD), as this classification system
also includes diagnostic codes for hypertension, over-
weight and obesity that could be combined or substituted
with clinical measurement values.
Conclusion
To our knowledge, this is the first study addressing the
impact of using different types of information to define a
condition on the assessment of prescribing quality. With
the increasing use of electronic health records, which
offer more complete information than administrative
data, EHR have the potential to provide sensitive esti-
mates of healthcare quality. Our study shows some draw-
backs of using either diagnostic codes or clinical
measurement values from the EHR for prescribing qual-
ity assessment. Although both approaches resulted in
missing patients who could benefit from the recom-
mended treatment, the use of clinical measurements is
more sensitive to screen for poorly treated patients. This
is important for quality improvement purposes. When
there is information bias in the documentation of diagno-
ses in relation to the treatment status, the use of diagnos-
tic codes alone can mislead both policy makers and
health care providers about the performance scores of
quality indicators. In such cases, a combination of diag-
nostic codes and clinical measurement information is
recommended for prescribing quality assessment.
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